Edition:
India

Keryx Biopharmaceuticals Inc (KERX.OQ)

KERX.OQ on NASDAQ Stock Exchange Capital Market

4.83USD
24 Nov 2017
Change (% chg)

$-0.04 (-0.82%)
Prev Close
$4.87
Open
$4.87
Day's High
$4.92
Day's Low
$4.80
Volume
116,273
Avg. Vol
374,777
52-wk High
$8.37
52-wk Low
$4.47

Chart for

About

Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally... (more)

Overall

Beta: 5.16
Market Cap(Mil.): $897.75
Shares Outstanding(Mil.): 118.75
Dividend: --
Yield (%): --

Financials

BRIEF-Keryx Biopharmaceuticals Q3 loss per share $0.20

* Keryx Biopharmaceuticals announces third quarter 2017 financial results

07 Nov 2017

BRIEF-KERYX BIOPHARMACEUTICALS SAYS MICHAEL ROGERS APPOINTED CHAIRMAN OF BOARD

* KERYX BIOPHARMACEUTICALS ANNOUNCES CHANGES TO ITS BOARD OF DIRECTORS

14 Sep 2017

BRIEF-Keryx Biopharmaceuticals Inc - co and Patheon Inc entered into a product agreement - SEC filing​

* Keryx Biopharmaceuticals Inc - co and Patheon Inc entered into a product agreement - SEC filing​

02 Sep 2017

BRIEF-Keryx Biopharmaceuticals Q2 loss per share $0.77

* Keryx Biopharmaceuticals announces second quarter 2017 financial results and increased 2017 u.s. Product sales guidance

27 Jul 2017

Competitors

  Price Chg
Sanofi SA (SASY.PA) €77.45 -0.09
Fresenius Medical Care AG & Co. KGaA (FMEG.DE) €82.35 -0.15
Shire PLC (SHP.L) 3,711.00 -24.00
Shire PLC (3159084.L) -- --

Earnings vs. Estimates